Investor Type | Firm |
Type of Fund | Private Equity Fund |
Industries | Software (Web Marketplace Saas..) • Education • BioTech • Businesses Solutions • Hardware (& Manufacturing) • Retail (& E-Commerce) • CleanTech • A.I. (& Big Data) • HealthTech (& Fitness) • Advertising • Material Science • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Life Science • Consumer |
Stages | Expansion, MBO/LBO, Acquisition, Recapitalization, Seed, Series A, Venture, Series B |
Investing | United States • Canada • Europe • Ireland |
Investment Range | $10,000,000 - $30,000,000 |
Assets Under Management | $1,500,000,000 |
Ampersand Capital Partners is a private equity fund with an extensive focus on the healthcare and life sciences sectors. They pride themselves on a 'founder-focused' approach, working in close partnership with portfolio companies’ founders and leadership teams to craft leaders in the healthcare and life sciences domains. Ampersand operates with the philosophy that maintaining founders in leading roles facilitates the realization of the company's vision, while the experienced team at Ampersand provides strategic support, leveraging their deep industry knowledge and resources to promote innovation and successful outcomes. Their portfolio showcases a range of companies that span various segments within the life sciences sector, including laboratory products, laboratory services, contract manufacturing, pharma services, and specialty pharma. Ampersand boasts over 30 years of commitment to life sciences with a global reach, having offices in North America and Europe. The firm offers expansion, MBO/LBO, acquisition, recapitalization, seed, Series A, venture, and Series B investments. Their expertise in equity investments and preference for company sizes typically ranging from $10 million to $30 million in equity, positions typically held in both majority or minority positions. Geographically, their interests span North America, Europe, and the APAC regions. Ampersand’s assets under management total around $1.5 billion, underscoring their substantial role in the investment landscape. The firm's notable industry insight contributes to its recognition as a leader and a 'Top Performing Private Equity Fund Manager' as acknowledged by third-party assessments.